by University of Texas M. D. Anderson Cancer Center Hodgkin lymphoma, nodular lymphocyte predominant (high-power view) Credit: Gabriel Caponetti, MD./Wikipedia/CC BY-SA 3.0 Results from the ZUMA-12 trial led by researchers at The University of Texas MD Anderson Cancer Center showed that first-line treatment with axicabtagene ciloleucel (axi-cel), a chimeric antigen receptor (CAR) T cell therapy,...
